Xavier Durando

Has grant

PU-PH Head of oncology department Clinical Research Director

France

Research Interests

Explore related searches

Professors in France Professors in Immunology Immunology professors in France

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Xavier Durando is the Head of the Oncology Department and Clinical Research Director at the Centre Jean Perrin in France. His research focuses on predictive and prognostic factors in various cancers, including ovarian and breast cancer, with recent contributions to studies on neoadjuvant therapies and innovative treatment strategies. Additionally, Professor Durando is involved in developing federated data mining tools to enhance cancer research collaboration.

Recent Grants

Grant: Close

Clinical research unit of the Jean Perrin centre

Open Date: 2011-01-24

Close Date: 2015-01-24

Articles (11)

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (3)

Aurélie bertaut

Head of methodology and biostatistic unit

Centre Georges-François Leclerc

FRANCE

View details

Jean-Jacques Lemaire

Université Clermont Auvergne

FRANCE

View details

Emmanuel Desandes

Paris university

FRANCE

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Xavier Durando

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (11)

Predictive and Prognostic Factors in Epithelial Ovarian Cancer: A Review

Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial

Consore: A Powerful Federated Data Mining Tool Driving a French Research Network to Accelerate Cancer Research

A Multicenter Randomized Bioequivalence Study of a Novel Ready-to-Use Temozolomide Oral Suspension vs. Temozolomide Capsules

Prediction of residual disease using circulating DNA detection after potentiated radiotherapy for locally advanced head and neck cancer (NeckTAR): a study protocol for a prospective, multicentre trial

Targeted Treatment of Advanced Endometrial Cancer: Focus on Pembrolizumab

Preoperative stereotactic radiosurgery for brain metastases: the STEP study protocol for a multicentre, prospective, phase-II trial

Eosinophil counts as a relevant prognostic marker for response to nivolumab in the management of renal cell carcinoma: a retrospective study

Platelet-to-Lymphocyte Ratio Is Associated With Favorable Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: A Study on 120 Patients.

XENOBREAST Trial: A prospective study of xenografts establishment from surgical specimens of patients with triple negative or luminal b breast cancer

Durable Response to Crizotinib in a Patient with Pulmonary Adenocarcinoma Harboring MET Intron 14 Mutation: A Case Report

Collaborators (3)

Aurélie bertaut

Jean-Jacques Lemaire

Emmanuel Desandes

Make your next move.